Treatment-free survival after discontinuation of immune checkpoint inhibitors in patients with objective response
| Study (trial identifier) | Responders (n) | Responders who discontinued ICI (n) | Median TFS (months) | Ongoing response off-treatment (%)* |
| Amin et al33 (CheckMate 016) | 18 | 12 | 9.4 | 25.0 |
| Amin et al33 (CheckMate 016) | 9 | 5 | 0.5 | 0.0 |
| Atkins et al39 (NCT02133742) | 38 | 16 | 0.8 | 43.8 |
| Choueiri et al40 (JAVELIN Renal 101) | 232 | 79 | 0.5 | 7.6 |
| Dudek et al34 (BTCRC-GU14-003) | 5 | 5 | 0.0 | 0.0 |
| Dudek et al34 (BTCRC-GU14-003) | 28 | 27 | 4.2 | 11.1 |
| Hammers et al35 (CheckMate 016) | 19 | 12 | 4.6 | 41.7 |
| Hammers et al35 (CheckMate 016) | 19 | 15 | 1.7 | 33.3 |
| McKay et al41 (OMNIVORE) | 10 | 10 | 6.5 | 70.0 |
| Motzer et al37 (CheckMate 025) | 94 | 86 | 1.7 | 16.3 |
| Motzer et al42 (CheckMate 214) | 59† | 39 | 23.5 | 61.5 |
| Naing et al43 (IVY) | 14 | 6 | 11.8 | 83.3 |
| Ornstein et al18 (NCT03126331) | 5‡ | 5 | 7.8 | 80.0 |
| Topalian et al38 (CA209-003) | 10 | 5§ | 13.5 | 40.0 |
| Vaishampayan et al36 (JAVELIN Solid Tumor) | 10 | 3¶ | 1.0 | 0.0 |
| Vaishampayan et al36 (JAVELIN Solid Tumor) | 2 | 2 | 3.3 | 50.0 |
*Of responders who discontinued ICI.
†Complete responders only.
‡Includes one patient with stable disease.
§Does not include patients who discontinued ICI following progressive disease, as study did not report whether subsequent systemic therapy was started.
¶Does not include patients who discontinued ICI following progressive disease, as study did not report events after progression.
ICI, immune checkpoint inhibitors; TFS, treatment-free survival in responders who discontinued ICI.